Analyst Price Target is $25.17
▲ +81.71% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Scholar Rock in the last 3 months. The average price target is $25.17, with a high forecast of $30.00 and a low forecast of $20.00. The average price target represents a 81.71% upside from the last price of $13.85.
Current Consensus is
Buy
The current consensus among 6 investment analysts is to buy stock in Scholar Rock. This Buy consensus rating has held steady for over two years.
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Read More
